| Primary |
| Breast Cancer |
33.7% |
| Diffuse Large B-cell Lymphoma |
15.5% |
| Hodgkin's Disease |
8.2% |
| B-cell Lymphoma |
7.0% |
| Burkitt's Lymphoma |
6.1% |
| Product Used For Unknown Indication |
5.2% |
| Neutropenia |
3.5% |
| Non-hodgkin's Lymphoma |
3.5% |
| Prophylaxis |
3.2% |
| Osteosarcoma Metastatic |
2.7% |
| Uterine Leiomyosarcoma |
2.4% |
| Sarcoma |
2.0% |
| Chemotherapy |
1.2% |
| Acute Lymphocytic Leukaemia |
1.0% |
| Blood Stem Cell Harvest |
0.9% |
| Febrile Neutropenia |
0.9% |
| Hypertension |
0.9% |
| Breast Cancer Metastatic |
0.8% |
| Depression |
0.6% |
| Hepatitis Viral |
0.6% |
|
| Febrile Neutropenia |
22.8% |
| Neutropenia |
9.8% |
| Left Ventricular Dysfunction |
6.5% |
| Pyrexia |
4.9% |
| Rash |
4.9% |
| Vomiting |
4.9% |
| Anaemia |
4.1% |
| Cardiomyopathy |
4.1% |
| Pulmonary Fibrosis |
4.1% |
| Syncope |
4.1% |
| Thrombocytopenia |
4.1% |
| White Blood Cell Count Increased |
4.1% |
| Atrial Fibrillation |
3.3% |
| Dehydration |
3.3% |
| Neutropenic Sepsis |
3.3% |
| Acute Myeloid Leukaemia |
2.4% |
| B-cell Lymphoma |
2.4% |
| Device Related Infection |
2.4% |
| Haemoglobin Decreased |
2.4% |
| Pneumonitis |
2.4% |
|
| Secondary |
| Diffuse Large B-cell Lymphoma |
17.5% |
| Product Used For Unknown Indication |
13.4% |
| Burkitt's Lymphoma |
9.7% |
| Acute Myeloid Leukaemia |
8.9% |
| Breast Cancer |
6.9% |
| Burkitt's Leukaemia |
6.2% |
| Prophylaxis |
5.6% |
| B-cell Lymphoma |
4.8% |
| Peripheral T-cell Lymphoma Unspecified |
3.3% |
| Burkitt's Lymphoma Stage Iv |
3.3% |
| Hodgkin's Disease |
2.9% |
| Malignant Lymphoid Neoplasm |
2.6% |
| T-cell Lymphoma |
2.5% |
| Sarcoma |
2.2% |
| Drug Use For Unknown Indication |
2.0% |
| Plasma Cell Myeloma |
1.9% |
| Acute Lymphocytic Leukaemia |
1.9% |
| Non-hodgkin's Lymphoma |
1.6% |
| Hypertension |
1.5% |
| Deep Vein Thrombosis |
1.4% |
|
| Febrile Neutropenia |
9.7% |
| Pyrexia |
6.7% |
| Neutropenia |
6.0% |
| Maternal Exposure Before Pregnancy |
5.6% |
| Thrombocytopenia |
5.6% |
| Vomiting |
5.6% |
| Constipation |
5.2% |
| Death |
5.2% |
| Sepsis |
5.2% |
| Anaemia |
4.9% |
| Neutrophil Pelger-huet Anomaly Present |
4.9% |
| Pneumonia |
4.9% |
| Pulmonary Embolism |
4.9% |
| Infection |
4.5% |
| Syncope |
4.1% |
| Gastric Ulcer Haemorrhage |
3.7% |
| Neutropenic Sepsis |
3.7% |
| Stomatitis |
3.4% |
| Cytokine Release Syndrome |
3.0% |
| Leukaemia Recurrent |
3.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.5% |
| Prophylaxis |
17.6% |
| Aplastic Anaemia |
9.4% |
| Infection Prophylaxis |
8.8% |
| Drug Use For Unknown Indication |
7.8% |
| Premedication |
4.2% |
| Prophylaxis Against Graft Versus Host Disease |
3.4% |
| Bone Marrow Conditioning Regimen |
3.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
2.4% |
| Constipation |
2.3% |
| Antiviral Prophylaxis |
2.3% |
| Hypertension |
2.1% |
| Antifungal Prophylaxis |
2.1% |
| Neutropenia |
2.0% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Diffuse Large B-cell Lymphoma |
2.0% |
| Breast Cancer |
1.9% |
| Mantle Cell Lymphoma |
1.8% |
| Multiple Myeloma |
1.7% |
| Pain |
1.7% |
|
| White Blood Cell Count Decreased |
15.2% |
| Thrombocytopenia |
9.6% |
| Febrile Neutropenia |
8.2% |
| Neutropenia |
7.9% |
| Pyrexia |
7.1% |
| Sepsis |
6.4% |
| Vomiting |
5.9% |
| Pneumonia |
5.2% |
| Death |
4.4% |
| Respiratory Failure |
3.6% |
| Renal Failure |
3.4% |
| Septic Shock |
3.4% |
| Acute Myeloid Leukaemia |
2.9% |
| Therapeutic Response Decreased |
2.7% |
| Infection |
2.6% |
| Interstitial Lung Disease |
2.6% |
| Pancytopenia |
2.5% |
| Multi-organ Failure |
2.3% |
| Thrombotic Microangiopathy |
2.1% |
| Acute Graft Versus Host Disease In Skin |
2.0% |
|
| Interacting |
| Product Used For Unknown Indication |
100.0% |
|
| Bone Marrow Failure |
100.0% |
|
